Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Sold by Ikarian Capital LLC

Ikarian Capital LLC decreased its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 33.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 100,609 shares of the company’s stock after selling 51,212 shares during the quarter. Ikarian Capital LLC’s holdings in Roivant Sciences were worth $1,060,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of ROIV. Vanguard Group Inc. boosted its position in shares of Roivant Sciences by 159.1% during the 3rd quarter. Vanguard Group Inc. now owns 5,602,566 shares of the company’s stock valued at $65,438,000 after acquiring an additional 3,440,374 shares during the last quarter. DAVENPORT & Co LLC boosted its position in shares of Roivant Sciences by 1.8% during the 4th quarter. DAVENPORT & Co LLC now owns 283,080 shares of the company’s stock valued at $3,179,000 after acquiring an additional 5,100 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of Roivant Sciences by 369.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 92,989 shares of the company’s stock valued at $1,044,000 after acquiring an additional 73,192 shares during the last quarter. Arizona State Retirement System raised its holdings in Roivant Sciences by 18.4% in the 4th quarter. Arizona State Retirement System now owns 77,558 shares of the company’s stock valued at $871,000 after buying an additional 12,057 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Roivant Sciences by 25.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 51,170 shares of the company’s stock valued at $575,000 after buying an additional 10,319 shares during the period. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Stock Down 2.1 %

Shares of ROIV stock traded down $0.23 during trading hours on Thursday, reaching $10.62. 3,475,693 shares of the stock were exchanged, compared to its average volume of 5,874,417. The business’s fifty day moving average is $10.82 and its two-hundred day moving average is $10.87. The company has a debt-to-equity ratio of 0.07, a current ratio of 25.24 and a quick ratio of 25.24. Roivant Sciences Ltd. has a 12-month low of $8.24 and a 12-month high of $13.24. The firm has a market capitalization of $7.85 billion, a P/E ratio of 2.10 and a beta of 1.24.

Roivant Sciences (NASDAQ:ROIV) last released its earnings results on Thursday, May 30th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.03. Roivant Sciences had a net margin of 3,484.86% and a negative return on equity of 25.05%. The firm had revenue of $28.93 million for the quarter, compared to analyst estimates of $32.46 million. As a group, research analysts expect that Roivant Sciences Ltd. will post -1.12 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ROIV has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Roivant Sciences from $14.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Piper Sandler boosted their price objective on shares of Roivant Sciences from $20.00 to $22.00 and gave the company an “overweight” rating in a report on Wednesday, July 10th. The Goldman Sachs Group boosted their price objective on shares of Roivant Sciences from $16.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a report on Tuesday, June 18th. Finally, HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research note on Friday, May 31st. One analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, Roivant Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $17.10.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.